Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03467854 · ClinicalTrials.gov registry record
PK of Piperacillin/Tazobactam in Adults Undergoing ECMO
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 2
- Enrollment target
NCT03467854 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 2 participants.
The verdict
NCT03467854 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will have significant changes in concentration measurements, specifically an increased clearance rate and increased volume of distribution, during ECMO as compared to critically ill patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2024-09-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03467854
The ClinicalTrials.gov registry entry for NCT03467854 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03467854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03467854 about?
NCT03467854 is a clinical study titled "PK of Piperacillin/Tazobactam in Adults Undergoing ECMO". This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will have significant changes in concentra...
What is the current status of trial NCT03467854?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-01-01. Estimated completion is 2024-09-24.
Who is sponsoring clinical trial NCT03467854?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.